Core Insights - Capricor Therapeutics has appointed Dr. Michael Binks as Chief Medical Officer, effective immediately, to lead the advancement of deramiocel for Duchenne muscular dystrophy (DMD) and future pipeline opportunities [1][2] - Dr. Binks has 25 years of experience in clinical development and has held senior roles at Pfizer and GlaxoSmithKline, contributing to the advancement of several first-in-class therapies [2] - Capricor's lead product candidate, deramiocel, is in late-stage development and has shown potent immunomodulatory and anti-fibrotic actions in preserving cardiac and skeletal muscle function in dystrophiopathies [3] Company Overview - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases, with a commitment to innovative treatments [3] - The company has entered into an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of deramiocel for DMD in the United States and Japan, pending regulatory approval [6]